Moleculin Biotech (Nasdaq: MBRX) reported that annamycin (naxtarubicin), its liposomal anthracycline candidate, produced complete remission rates roughly three times higher than the control arm in a preliminary interim analysis of the pivotal MIRACLE trial — data that, if sustained in the full study population, would position the drug as a meaningful option in relapsed or refractory acute myeloid leukemia, a setting where effective salvage chemotherapy remains scarce. The trial enrolled a heavily pretreated population, with nearly a third of patients having received venetoclax-based regimens as frontline therapy, a group historically associated with poor outcomes on subsequent treatment.
The interim analysis covered the first 45 patients enrolled in Part A of the Phase II/III adaptive study. On the primary endpoint of complete remission, the two annamycin dose arms — 190 mg/m² plus high-dose cytarabine and 230 mg/m² plus high-dose cytarabine — achieved CR rates of 43% and 36%, respectively, compared with 12% for the placebo plus high-dose cytarabine control. Composite complete remission, which includes CR with incomplete blood count recovery, reached 50% and 57% in the respective annamycin arms versus 29% for control. The trial's Independent Data Monitoring Committee reviewed the data and unanimously concluded that the numeric trend favored both annamycin arms and that there was sufficient evidence of efficacy to continue the study without dropping either dose arm.
All response data in this interim analysis reflect outcomes after only one cycle of therapy, as specified by the MIRACLE protocol. Historical benchmarks in R/R AML — including the MIRROS and CLASSIC I studies, as well as Moleculin's own earlier MB-106 study — permitted multiple treatment cycles before response assessment, which typically inflates absolute remission rates. The company argues that the most meaningful comparison is the relative performance of annamycin versus the concurrent randomized control arm evaluated under identical single-cycle conditions. On that basis, the approximately three-fold CR advantage is difficult to dismiss, even at n=45. Cross-trial comparisons with historical datasets, however, should be made with caution and cannot be used to claim superiority over established agents.
Competitive context
The R/R AML treatment landscape has expanded substantially in recent years, with most recent approvals targeting genetically defined AML subsets (FLT3, IDH1, IDH2, KMT2A, NPM1), leaving patients without actionable mutations or those progressing after venetoclax with relatively few options. Annamycin's proposed niche is the biomarker-agnostic, venetoclax-pretreated population. The drug is structurally modified to evade P-glycoprotein-mediated multidrug resistance efflux, a mechanism that compromises the efficacy of conventional anthracyclines in relapsed disease. It is also engineered to reduce the cardiotoxicity associated with standard anthracyclines such as doxorubicin.